Ocular Therapeutix
OCUL
168 hedge funds and large institutions have $1.22B invested in Ocular Therapeutix in 2024 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 42 increasing their positions, 49 reducing their positions, and 16 closing their positions.
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
30% more capital invested
Capital invested by funds: $940M → $1.22B (+$280M)
12% more funds holding
Funds holding: 150 → 168 (+18)
1.07% more ownership
Funds ownership: 88.69% → 89.76% (+1.1%)
14% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 49
26% less call options, than puts
Call options by funds: $2.34M | Put options by funds: $3.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$23.3M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$8.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$8.24M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$5.85M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.6M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$13M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.49M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.71M |
| 5 |
SR
Summer Road
West Palm Beach,
Florida
|
-$4.02M |
OCUL Hedge Fund Activity: Q3 2024 in Review
168 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2024, worth a combined $1.22B — up 30% from $940M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new OCUL positions and 16 closed out — a net gain of 18 holders — while 42 added to existing stakes and 49 trimmed.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $23.3M. The largest seller was Logos Global Management, cutting an estimated $13.6M.
- 168 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2024, up from 150 in Q2 2024.
- Funds reported $1.22B of Ocular Therapeutix stock for Q3 2024, up 30% quarter-over-quarter.
- 34 funds opened new Ocular Therapeutix positions in Q3 2024 and 16 closed out, a net change of +18 holders.
- The largest Ocular Therapeutix buyer in Q3 2024 was Assenagon Asset Management, an estimated $23.3M added.
- The largest Ocular Therapeutix seller in Q3 2024 was Logos Global Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2024.